Found 411 results in Expert Content

Summary: A panel of drug developers discuss innovative trial designs, on-demand manufacturing, communicating between clinical partners, prepping a strong regulatory submission and enabling faster decision making in your phase I trial.

Summary: Download this executive summary article to learn about best practices and strategies to mitigate risks and ensure a successful tech transfer from development through to commercial scale spray drying of pharmaceutical products.

Summary: Experts provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon.

Summary: In this Q&A article, Catalent experts Carolyn Berg and Carla Vozone discuss innovations in orally inhaled drug products, in particular dry powders for inhalation.

Intranasal delivery is emerging as an alternative route of systemic drug delivery for a variety of indications such as migraine, seizures, breakthrough pain and opioid overdose and more.

Summary: Download this executive summary to learn more about safe and successful HPAPI product development and manufacturing using micronization.

Summary: As drug developers look to address unmet medical needs for orphan diseases, working with experienced partners can help in navigating key challenges such as a limited active pharmaceutical ingredient supply, efficient small-scale manufacturing for small patient populations and distribution logistics

Summary: To rapidly screen macromolecules’ potential for oral delivery, it is critical to assess multiple enabling technologies in parallel, targeting different biological barriers.

Summary: Decisions made throughout early and mid-stage clinical trials impact late-stage results and sometimes, entire programs and companies. Since some obstacles can prove overwhelming for startups, there is a lot to learn from those who successfully walked the path.

Read this case study to learn about how Catalent deployed its integrated OneXpress® Solution to expedite the transfer of a partner program to one of its late-stage manufacturing sites while optimizing the utilization of a limited supply of API.